// startup autopsy
NeuroTherapeutics Pharma
Chasing brain cures until the money ran out
marketfitSlow Death
Years-long decline before final shutdown · Fatal mistake: NeuroTherapeutics Pharma burned through $58.2M in clinical trials without securing a partnership or achieving sufficient efficacy milestones to attract additional investment.
Key Events Timeline
FOUNDING
NeuroTherapeutics Pharma founded in the USA to develop CNS drug candidates targeting neurological disorders.
FUNDING
Company raises significant capital to fund Phase II clinical trials for its lead CNS compound.
FUNDING
Final funding round closes, bringing total to $58.2M; investors grow cautious amid lack of efficacy data from trials.
LAYOFF
Company begins reducing headcount as clinical programs stall and runway shortens.
SHUTDOWN
NeuroTherapeutics Pharma ceases operations after exhausting all funding without achieving FDA approval or licensing deal.